Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...
SiliconRepublic42m
Pfizer to cut more than 200 jobs at Irish sites
The job cuts are part of a large cost-cutting programme at Pfizer and follow jobs it made to its Newbridge site last year.
FiercePharma18h
Pfizer gins up £2.4B after unloading hundreds of millions of Haleon shares
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
Newstalk3h
210 jobs to be cut by Pfizer
Sinn Féin's Donnchadh Ó Laoghaire said he hopes the Government will help and support workers impacted by tonight's news.
Budget fallout while Pfizer slashes Irish jobs
In Commercial Property, Ronald Quinlan reports that The Queen’s pub in Dalkey is back on the market for €3.45 million. He ...
FiercePharma15h
Amid large cost-cutting drive, Pfizer plans manufacturing layoffs in Ireland
No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...
Medscape2d
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
sicklecellanemianews17h
Pfizer withdraws Oxbryta from global markets, cites safety concerns
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...